Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.本研究为一项I期临床试验，旨在评估塞利尼索（selinexor）的安全性与耐受性，并确定其用于晚期或转移性实体瘤的II期推荐剂量（RP2D）。